🔴 LQDA is trading 4.5% down today on profit-taking after a sharp multi-day rally

LQDA is trading 4.5% down at $74.66 as the stock enters a period of consolidation following a significant multi-day rally.

• The recent surge was driven by strong Q1 2026 financial results and continued optimism surrounding the company's YUTREPIA pulmonary hypertension therapy.
• After trading near all-time highs, the current decline is likely attributed to profit-taking rather than any new negative, company-specific catalysts.
• The stock remains well-positioned following robust earnings and positive clinical data regarding its core treatment pipeline.